Objective:To investigate the antitumor activity of the compound HS-4 and the action mechanism.Methods:MTT method was used to test in vitro antitumor activity of the compound HS-4.Orthotopic xenotransplantation tumor m...Objective:To investigate the antitumor activity of the compound HS-4 and the action mechanism.Methods:MTT method was used to test in vitro antitumor activity of the compound HS-4.Orthotopic xenotransplantation tumor model of liver cancer was established in nude mice,and.in vivo antitumor activity of compound HS-4 was tested with a small animal in-vivo imaging system.Sequencing of small RNA library and RNA library was performed in HS-4 treated tumor cell group and control group to investigate the anti-cancer mechanism of HS-4 at level of functional genomics,using high-throughput sequencing technology.Results:HS-4 was found to have relatively high in-vitro antitumor activity against liver cancer cells,gastric cancer cells,renal cancer cells,lung cancer cells,breast cancer cells and colon cancer cells.The IC_(50) values against SMMC-7721 and Bel-7402 of liver cancer cells were 0.14 and 0.13 nmol/L respectively,while the IC_(50) values against MGC-803 and SGC-7901 of gastric cancer cells were 0.19 and 0.21 nmol/L,respectively.It was demonstrated that HS- 4 possessed a betler therapeutic effect in liver cancer.Conclusions:A new reliable orthotopicxenotransplantation tumor model of liver cancer in nude mice is established.The new compounds HS-4 was found to possess relatively high in vivo and in vitro antitumor activity against liver cancer cells.展开更多
目的观察血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎的临床疗效。方法选取2012年1月—2015年12月在南京市第一医院住院治疗的重症病毒性肺炎患者92例,随机分为对照组和治疗组,每组各46例。对照组患者静脉注射静注人免疫球蛋白(p H...目的观察血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎的临床疗效。方法选取2012年1月—2015年12月在南京市第一医院住院治疗的重症病毒性肺炎患者92例,随机分为对照组和治疗组,每组各46例。对照组患者静脉注射静注人免疫球蛋白(p H 4),10 g/次,1次/d;治疗组在对照组的基础上静脉注射血必净注射液,50 m L/次,2次/d。两组患者均连续治疗7 d。治疗后,比较两组患者临床疗效、临床症状体征改善及高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的水平改变。结果治疗后,对照组和治疗组的总有效率分别为82.61%和91.30%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,治疗组患者退热时间、咳嗽和气喘消退时间明显短于对照组,两组临床症状体征改善情况比较差异有统计学意义(P<0.05)。治疗后,两组患者hs-CRP、IL-6、TNF-α水平均明显降低,同组治疗前后比较具有统计学意义(P<0.05);且治疗组上述炎症因子降低程度更明显,两组比较差异具有统计学意义(P<0.05)。结论血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎临床疗效显著,能有效改善患者的症状体征和炎症因子,具有一定的临床推广应用价值。展开更多
基金supported by National Natural Science Foundation of China(No.81160408)
文摘Objective:To investigate the antitumor activity of the compound HS-4 and the action mechanism.Methods:MTT method was used to test in vitro antitumor activity of the compound HS-4.Orthotopic xenotransplantation tumor model of liver cancer was established in nude mice,and.in vivo antitumor activity of compound HS-4 was tested with a small animal in-vivo imaging system.Sequencing of small RNA library and RNA library was performed in HS-4 treated tumor cell group and control group to investigate the anti-cancer mechanism of HS-4 at level of functional genomics,using high-throughput sequencing technology.Results:HS-4 was found to have relatively high in-vitro antitumor activity against liver cancer cells,gastric cancer cells,renal cancer cells,lung cancer cells,breast cancer cells and colon cancer cells.The IC_(50) values against SMMC-7721 and Bel-7402 of liver cancer cells were 0.14 and 0.13 nmol/L respectively,while the IC_(50) values against MGC-803 and SGC-7901 of gastric cancer cells were 0.19 and 0.21 nmol/L,respectively.It was demonstrated that HS- 4 possessed a betler therapeutic effect in liver cancer.Conclusions:A new reliable orthotopicxenotransplantation tumor model of liver cancer in nude mice is established.The new compounds HS-4 was found to possess relatively high in vivo and in vitro antitumor activity against liver cancer cells.
文摘目的观察血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎的临床疗效。方法选取2012年1月—2015年12月在南京市第一医院住院治疗的重症病毒性肺炎患者92例,随机分为对照组和治疗组,每组各46例。对照组患者静脉注射静注人免疫球蛋白(p H 4),10 g/次,1次/d;治疗组在对照组的基础上静脉注射血必净注射液,50 m L/次,2次/d。两组患者均连续治疗7 d。治疗后,比较两组患者临床疗效、临床症状体征改善及高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的水平改变。结果治疗后,对照组和治疗组的总有效率分别为82.61%和91.30%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,治疗组患者退热时间、咳嗽和气喘消退时间明显短于对照组,两组临床症状体征改善情况比较差异有统计学意义(P<0.05)。治疗后,两组患者hs-CRP、IL-6、TNF-α水平均明显降低,同组治疗前后比较具有统计学意义(P<0.05);且治疗组上述炎症因子降低程度更明显,两组比较差异具有统计学意义(P<0.05)。结论血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎临床疗效显著,能有效改善患者的症状体征和炎症因子,具有一定的临床推广应用价值。
